LivaNova (LIVN)
Builds heart-lung systems and implantable stimulation devices for epilepsy, depression and sleep apnea.
Something off on this page? Send us feedback.
Sells heart-lung machines, perfusion consumables and services for cardiac surgery alongside implantable nerve-stimulation devices for epilepsy and depression. The FDA-approved aura6000 sleep-apnea system remains prelaunch, while hospital purchasing, regulatory clearance and reimbursement shape adoption.
Designs and sells medical devices across Cardiopulmonary and Neuromodulation. Cardiopulmonary combines Essenz heart-lung machines with oxygenators, perfusion tubing, autotransfusion systems, cannulae, accessories and service for cardiac surgery. Neuromodulation centers on implantable VNS Therapy generators and leads for drug-resistant epilepsy and difficult-to-treat depression, while the FDA-approved aura6000 system for obstructive sleep apnea remains in prelaunch development.
Serves hospitals and specialists in more than 100 countries, with the United States as its largest market. The model pairs capital equipment with procedure-driven consumables and replacement implants, supported by direct sales teams and distributors. Product quality, regulatory approvals, clinical evidence and reimbursement shape adoption; oxygenator output also depends on specialized component supply. Heater-cooler claims and SNIA-related environmental obligations remain structural legal exposures.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 2, 2026 | Piper Sandler | Reiterate | Rating: —Target: $85 | Target: $90 |
| Aug 5, 2026 | Stifel Nicolaus | Target | Target: $80 | Target: $85 |
| Aug 5, 2026 | Needham | Reiterate | Rating: —Target: $81 | Target: $93 |
| Jul 15, 2026 | Mizuho Securities | Target | Target: $90 | Target: $95 |
| Jun 22, 2026 | KeyBanc | Reiterate | Rating: —Target: $81 | Target: $92 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $516.6M · Total debt $351.9M · Total assets $2.64B · Shareholders' equity $1.33B
- Revenue
- $390.6M
- Operating income
- $49.5M
- Net income
- $108.6M
No dividends on record.
| Institutions | 109.03% | 60.07M shares | |
|---|---|---|---|
| 310 holders · as of Jun 30, 2026 | |||
| Insiders | 0.41% | 224.5K shares | |
| 17 holders · as of Sep 14, 2026 | |||
| Adds to | 109.44% | ||
55.09M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 109.44%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 13.73% | 7.57M | as of Jun 30, 2026 |
Primecap Management Co/CA/Institution | 7.57% | 4.17M | as of Jun 30, 2026 |
FMR LLCInstitution | 5.71% | 3.15M | as of Jun 30, 2026 |
Hood River Capital Management LLCInstitution | 4.66% | 2.57M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 4.28% | 2.36M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Francesco Bianchi | director | −3,500 | $78.01 |
| Sep 4, 2026 | Brooke Story | director | −2,300 | $81.42 |
| Aug 31, 2026 | Francesco Bianchi | director | −1,650 | $79.72 |
| Aug 11, 2026 | Ahmet Tezel | officer: Chief Innovation Officer | −2,675 | $77.74 |
| Jun 15, 2026 | Francesco Bianchi | director | −1,200 | $80.19 |
- NeuroPace
Epilepsy-focused neuromodulation alternative to VNS Therapy
- Medtronic
Scale neuromodulation peer in DBS for epilepsy and brain stimulation
- Inspire Medical Systems
Direct OSA neurostimulation peer for the aura6000 program
- Haemonetics
Autotransfusion competitor through Cell Saver blood recovery systems
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LivaNova | $78.85 | +0.87% | $4.29B | 23.1 | 17.9 | 2.9 | +10.8% |
| NeuroPace | $14.84 | +2.06% | $495.7M | — | — | 5.0 | −3.0% |
| Medtronic | $91.41 | −0.37% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Inspire Medical Systems | $72.70 | −3.99% | $2.19B | 16.4 | 55.9 | 2.4 | −7.6% |
| Haemonetics | $108.71 | −0.02% | $4.94B | 53.3 | 19.7 | 3.7 | +5.6% |
| Median | 22.6 | 19.7 | 3.4 | +1.3% |